Wealth of Data for Fycompa® (perampanel) and Inovelon® (rufinamide) to be Presented at the American Epilepsy Society (AES) Annual Meeting

Hatfield, England (ots/PRNewswire) -

FOR EMEA MEDIA ONLY - NOT FOR SWISS/AUSTRIAN/US JOURNALISTS

Data from nine abstracts for Eisai's epilepsy treatments
perampanel and rufinamide will be presented at the 70th Annual
Meeting of the American Epilepsy Society (AES), 2-6 December,
Houston, Texas, which provide further insight into their long-term
use in people with epilepsy.

Perampanel is indicated in the European Union for patients aged 12
years and older, for adjunctive treatment of partial-onset seizures
(POS), with or without secondarily generalised seizures, and for
adjunctive treatment of primary generalised tonic-clonic (PGTC)
seizures in patients with idiopathic generalised epilepsy (IGE).[1]

Rufinamide is indicated in the European Union for the adjunctive
treatment of seizures associated with Lennox-Gastaut Syndrome in
patients with epilepsy aged four years and older.[2]

"These data provide real world insights into the activity of
perampanel and rufinamide in potential patients over a wide range of
ages. Through new and continued research with perampanel and
rufinamide, we aim to further educate the epilepsy community about
these debilitating diseases," comments Lynn Kramer, MD, Chief
Clinical Officer and Chief Medical Officer, Neurology Business Group,
Eisai.

The development of its epilepsy portfolio underscores Eisai's
human health care (hhc) mission, the company's commitment to
innovative solutions in disease prevention, cure and care for the
health and wellbeing of people worldwide. Eisai is committed to the
therapeutic area of neurology and to address the unmet medical needs
of people with neurological conditions and their families.

Perampanel abstracts at AES (presented in the George R Brown
Convention Center, Hall A3, Level 3):




Abstract Number Abstract details


Poster # 2.189 Evaluation of perampanel as monotherapy for
focal
Date: Sunday 4 seizures: experience from open-label
extension studies
December
Time: 10:00-16:00
Location: Hall A3, Kwan P, Mintzer S, Laurenza A, Patten A,
Cartwright K
B3


Poster # 2.190 Adjunctive perampanel (PER) in patients
(pts) with partial
Date: Sunday 4 seizures or primary generalized tonic-clonic
seizures
December (PGTCS): effect of age at diagnosis
Time: 10:00-16:00
Location: Hall A3, Kramer L, Patten A, Laurenza A, French JA
B3


Poster # 2.193 Long-term efficacy and safety of adjunctive
perampanel:
Date: Sunday 4 pooled analyses of the open-label extension
(OLE) studies
December
Time: 10:00-16:00
Location: Hall A3, Rektor I, Krauss GL, Inoue Y, Kaneko S,
Williams B, Patten
B3 A, Bibbiani F, Laurenza A, Wechsler RT


Poster # 2.222 A systematic review of real world perampanel